Events
Priavoid attends the AD/PD 2026 in Copenhagen between March 17 and 21. During the conference, Priavoid will be having an oral presentation and five poster presentations. Please find the full details on all presentations below:
Oral Presentation:
Abstract Title: The Abeta Oligomer Disassembling Compound PRI-002 Does Not Cause ARIA in an Ongoing Phase 2 Trial (ID 2426)
Presenting author: Prof. Dieter Willbold, MD, Priavoid GmbH
Date: March 17, 2026, at 3:30 pm CET
Time: 3:30 PM CET / 9:30 AM EST
Abstract number: TBD
Posters: Posters will be presented in one of the two shifts
Shift 1: Thursday, March 19, from 11:10 till 12:50
Abstract Title: #1803: Primus-AD: Design of the Phase 2 Study Treating Early AD Patients with the Novel Drug Candidate PRI-002
Presenting author: Dr. Dagmar Jürgens, Priavoid GmbH
Poster board number: SHIFT 01-323
Shift 2: Saturday, March 21, 17:00 – 19:00
Abstract Title: #514: Disassembly of α-Synuclein Aggregates by the All-D-Peptide PRI-101: Preclinical Efficacy In Vitro and In Vivo
Presenting author: Dr. Marc Sevenich, Priavoid GmbH
Poster board number: SHIFT 02-152
Abstract Title: #1265: The Aβ Targeting Compound PRI-002 Reduces Aβ Oligomers and Prevents Cognitive Decline in Various AD Animal Models
Presenting author: Dr. Sarah Schemmert, Priavoid GmbH
Poster board number: SHIFT 02-295
Abstract Title: #1621: Development of All-D-Peptides for the Disassembly of Toxic Tau Aggregates
Presenting author: Dr. Nadine Rösener, Priavoid GmbH
Poster board number: SHIFT 02-671
Abstract Title: #1619: Development of Therapeutic Compounds for the Disassembly of TDP-43 Aggregates as a Disease-Modifying Treatment for ALS and FTLD
Presenting author: Dr. Pauline Philippen, Priavoid GmbH
Poster board number: SHIFT 02-695
About Priavoid GmbH:
Priavoid GmbH is a clinical-stage drug developer. The company develops novel all-D-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS (amyotrophic lateral sclerosis) or tauopathies. All drug candidates are designed with an anti-prionic mechanism of action to dissolve neurotoxic protein aggregates. Priavoid is a spin-off of Heinrich Heine University Düsseldorf and Research Center Jülich and was founded in 2017. The company is privately financed, including by Qiagen co-founder Prof. em. Dr. Dr. h.c. Detlev Riesner.